Drug Profile
Capeserod - First Wave Biopharma
Alternative Names: SL-65.0155; SL-650155Latest Information Update: 05 Apr 2024
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Developer First Wave BioPharma; sanofi-aventis
- Class Anti-inflammatories; Antidementias; Urologics
- Mechanism of Action Serotonin 4 receptor agonists; Serotonin 4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Gastroparesis; Ulcerative colitis
- Discontinued Alzheimer's disease; Urinary incontinence
Most Recent Events
- 05 Apr 2024 First Wave Biopharma plans a meeting with the US FDA to establish a development and regulatory pathway for Capeserod in Gastrointestinal disorders with the intent to initiate clinical trials in 2025 (First Wave BioPharma SEC 2024)
- 18 Dec 2023 First Wave Biopharma plans a phase I trial in Gastroparesis (First Wave Biopharma pipeline, December 2023)
- 18 Dec 2023 First Wave Biopharma plans a phase I trial in Ulcerative colitis (In children) (First Wave Biopharma pipeline, December 2023)